This is an automatically translated article.
Arbosnew 50 is manufactured by the branch of Agimexpharm pharmaceutical joint stock company, the drug belongs to the group of hormonal drugs. In which cases is Arbosnew diabetes drug indicated?
1. What is Arbosnew 50?
Arbosnew 50 medicine has the main ingredient containing the active ingredient Acarbose with a concentration of 50 mg, prepared in the form of tablets, presented in a box of 3 blisters, 1 blister has 10 tablets.
2. Indications of the drug Arbosnew 50
Arbosnew is indicated for use in the following cases:
In monotherapy: used as an adjunct to diet and exercise for the treatment of type 2 diabetes (no side effects). insulin dependence) in individuals with hyperglycemia (especially postprandial hyperglycemia) that cannot be controlled by exercise and diet alone. In combination with a sulfonylurea used as an adjunct to diet and exercise in patients with type 2 diabetes mellitus in whom hyperglycemia is not controlled by Arbosnew or Sulfonylure alone.
3. Usage and dosage of Arbosnew 50
3.1. How to use Arbosnew 50 Patients need to take Arbosnew at the beginning of a meal to help reduce postprandial blood glucose levels. It is recommended that patients adhere to the dose prescribed by their doctor, as efficacy and tolerability vary and depend on each patient.
During initial therapy or when dose adjustment is required, it is necessary to measure glucose one hour after a meal in order to determine the degree of therapeutic response and the minimum effective dose of Arbosnew. Thereafter, hemoglobin glycosylate monitoring should be performed at approximately every 3 months (based on erythrocyte survival) so that long-term blood glucose control can be assessed.
3.2. Dosage of Arbosnew 50 Usual Adult Dose:
The recommended starting dose should be 50 mg/time, 3 times a day, but for relief of gastrointestinal symptoms starting at 50 mg/day. mg/time, 1 to 2 times a day and then increase the dose to the recommended dose if tolerated by the patient. After a period of 6 to 8 weeks of treatment, if the patient has not had an adequate clinical response, the dose may be increased to 100 mg 3 times a day and sometimes up to 200 mg/time, 3 times a day. If the patient experiences unpleasant complications due to strict adherence to the diet, no dose escalation should be made, but if necessary the dose can be reduced based on the severity of the adverse reactions and clinical reassessment by the treating physician. In low-weight patients at risk of serum transaminase elevations, only patients weighing more than 60 kg should receive a high dose of 50 mg three times a day. When the dose of 200 mg / time, 3 times a day, but the hemoglobin glycosylate or postprandial blood glucose cannot decrease any further, the dose should be reduced, and the effective dose tolerable should be maintained. In the elderly: use the usual adult dose.
In patients with renal failure with creatinine clearance < 25 ml/min/1.73 m2: Do not use Arbosnew in this subject.
It is not recommended to use Arbosnew in patients younger than 18 years of age.
4. Undesirable effects of the drug Arbosnew 50
During treatment with Arbosnew, patients may experience some unwanted effects as follows:
Common side effects such as: Broken stools, bloating, diarrhea, abdominal distention, nausea and pain . Rare side effects such as: abnormal liver function test indicators, itching, rash. Rare side effects such as hepatitis, jaundice, angioedema. Side effects of unknown frequency: thrombocytopenia, acute generalized exanthematous pustulosis syndrome, intestinal cystic gas, intestinal obstruction, enteritis, increased allergic reactions, drug sensitivities, hepatitis. The side effects will disappear when the patient stops using the drug, however, it is recommended that the patient immediately notify the doctor when experiencing abnormal symptoms affecting the treatment process for instructions on timely handling. time.
5. Arbosnew 50 . drug interactions
It is necessary to reduce the amount of sucrose during treatment with Arbosnew, because carbohydrates increase fermentation in the colon, so it often causes abdominal discomfort and sometimes diarrhea.
Arbosnew may interfere with the absorption or metabolism of iron. Because the mechanism of action of the antidiabetic drugs Biguanide or Sulfonylure and Arbosnew is different, when there is a combination of treatment, their effect on blood glucose control is additive.
It is necessary to avoid taking Cholestyramine, antacids, digestive enzymes, intestinal absorbers with Arbosnew, because they can reduce the effect of Arbosnew.
6. Note when using the drug Arbosnew 50
6.1. Contraindications of Arbosnew 50 Arbosnew is not contraindicated in the following subjects:
Patients with a history of hypersensitivity to Acarbose or any of the excipients of Arbosnew. Patients with inflammatory bowel disease, especially associated with ulcers. Patients with elevated liver enzymes, liver failure. Because Arbosnew has the ability to create gas in the intestinal tract, it should not be used in patients prone to pathology due to increased intra-abdominal pressure (hernia). Do not use in patients with hypoglycemia or diabetic ketoacidosis. Not for use by pregnant women and nursing mothers. 6.2. Precautions while using Arbosnew 50 It is necessary to monitor the patient's liver transaminases during treatment with Arbosnew, as cases of increased liver enzymes have been reported.
Caution should be exercised when Arbosnew is administered concomitantly with an insulin or sulfonylurea antidiabetic agent, as hypoglycemia may occur.
In patients with diabetes complicated by acidosis, coma or hyperketosis, Arbosnew has no effect when used alone, in which case insulin must be used.
This medicine contains lactose, so patients with hereditary problems such as galactose intolerance, glucose-galactose malabsorption, Lapp lactase deficiency should not use Arbosnew.
Arbosnew has no symptoms that affect the ability to drive and use other machines.
7. Preservation of Arbosnew 50
Store Arbosnew at a temperature below 30 degrees Celsius, keep in a cool, dry place, avoid direct exposure to sunlight or high temperature, because it can change the ingredients present in Arbosnew . Keep out of reach of small children to avoid accidental ingestion.
Arbosnew drug has a shelf life of 36 months from the date of manufacture, before use, it is necessary to check the expiry date carefully, tablets with color changes, moldy, watery should not be used.
The above are the main uses of the drug Arbosnew 50, patients need to carefully read the instructions before using and follow the instructions of a specialist doctor to get the best results.
